Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

RNC Pharma Database Update: Pharmaceutical Drug Production in Russia (October 2018)

Thursday, December 6, 2018

Between January and October 2018, Russia produced 276.2 mln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 1.9% higher than that of the same period of 2017. The positive dynamics are mostly due to the active work of manufacturers. In physicals terms though, Russia produced 3.3 bln units of pharmaceuticals, which is 9.4% lower than that of the same period of 2017.

If calculated in minimum dosage units (MDU), the dynamics in physical terms are a bit higher, -3.9%. While the average unit of an OTC drug has not considerably changed, the average unit of an Rx drug has become bigger. However, the dynamics of the Rx drug production in physical terms are +3.1%, if calculated in MDU. Between January and October 2018, Russian manufacturers produced 55.3 bln MDUs.

The dynamics of the pharmaceutical drug production in October 2018 in monetary terms are 16%, while those in physical terms are -0.8%.

87 out of 160 OTC drug manufacturers have decreased their production in physical terms. The Russian pharmaceutical market leaders are among them, in particular Pharmastandard. Samaramedprom has the biggest decrease among the top 15 manufacturers (-35%); they have decreased the production of more than half products from their product line, with the production of Licorice root syrup having fallen by 56%. Slavyanskaya Apteka has the best dynamics (+57%), with the production of Naphtyzin having risen by 62%.

As for Rx drug manufacturers, 140 of 280 have decreased their production in physical terms. Among the top 15 producers, Marathon Pharma has the biggest decrease (-27%), with Metronidazol production having fallen by 61%, followed by Ozon (-21%), whose Ciprofloxacin has the biggest decrease (-51%.) Vetrex and Grotex have the biggest production increase (+30% and +18%.) The production of Losartan and Betahistine by Vetrex has risen by 75% and 65%, respectively. The production of Lidocaine and Piracetam by Gortex has risen by 71% and 65%, respectively.

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – October 2018)